Back to Search
Start Over
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
- Source :
- European Respiratory Journal. 59:2102419
- Publication Year :
- 2021
- Publisher :
- European Respiratory Society (ERS), 2021.
-
Abstract
- IntroductionContemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators.MethodsWe evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan–Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches.ResultsAt baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk.ConclusionsThe four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach.
- Subjects :
- Pulmonary and Respiratory Medicine
medicine.medical_specialty
Portopulmonary hypertension
Heart disease
business.industry
medicine.drug_class
Walk distance
External validation
Risk management tools
medicine.disease
Pulmonary hypertension
3. Good health
03 medical and health sciences
0302 clinical medicine
030228 respiratory system
Internal medicine
medicine
Natriuretic peptide
030212 general & internal medicine
Risk assessment
business
Subjects
Details
- ISSN :
- 13993003 and 09031936
- Volume :
- 59
- Database :
- OpenAIRE
- Journal :
- European Respiratory Journal
- Accession number :
- edsair.doi...........7d87bc885e6c9a768cd4fbc90e6ed3ff